Review anchor
Potassium voltage-gated channel subfamily A member 5
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Potassium voltage-gated channel subfamily A member 5
CHEMBL4306
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Potassium voltage-gated channel subfamily A member 5 as ChEMBL target CHEMBL4306, mapped to UniProt P22460. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL4306
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P22460
Potassium voltage-gated channel subfamily A member 5
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Potassium voltage-gated channel subfamily A member 5 matters
Potassium voltage-gated channel subfamily A member 5 is reviewed as Potassium voltage-gated channel subfamily A member 5 (UniProt P22460); Potassium voltage-gated channel subfamily A member 5 shows approved-linked disease relevance led by atrial fibrillation. 1 more disease program remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 6 approved drugs, 1148 compounds, and 127 assays, with lead potency reaching pChEMBL 8.1.
Protein context
Potassium voltage-gated channel subfamily A member 5
Potassium voltage-gated channel subfamily A member 5 Sequence length is 613 aa.
Review this target as Potassium voltage-gated channel subfamily A member 5, mapped to UniProt P22460. Sequence length is 613 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P22460
Protein
Disease context
atrial fibrillation
Potassium voltage-gated channel subfamily A member 5 shows approved-linked disease relevance led by atrial fibrillation. 1 more disease program remain visible in the same review block. 1 linked drug keep the rationale reviewable. 1 additional disease programs remain visible in the same card. Linked drugs include VERNAKALANT HYDROCHLORIDE.
Start review with atrial fibrillation because it currently carries approved-linked support. Linked drugs include VERNAKALANT HYDROCHLORIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
1 linked drug
Activity base
Portfolio and assay base
ChEMBL currently tracks 6 approved drugs, 1148 compounds, and 127 assays for this target. The dominant activity type is IC50. CHEMBL1256851 is the current potency anchor at pChEMBL 8.1.
Use CHEMBL1256851 as the tractability anchor when discussing potency (pChEMBL 8.1).
Activity source · ChEMBL 36 via Core Engine
6 approved
pChEMBL 8.1
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Potassium voltage-gated channel subfamily A member 5 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P22460, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why atrial fibrillation is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
1148
Total Compounds
127
Total Assays
6
Approved Drugs
IC50: 908.0, EC50: 39.0, KD: 5.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL1256851
|
8.1 | IC50 | — |
|
|
No preferred name
CHEMBL4065169
|
8.1 | IC50 | — |
|
|
No preferred name
CHEMBL3940526
|
8.0 | EC50 | — |
|
|
No preferred name
CHEMBL3961395
|
8.0 | EC50 | — |
|
|
No preferred name
CHEMBL4104525
|
8.0 | IC50 | — |
Source Header